Following the decision by the National Government Services to end its local coverage determination for both cellular and tissue-based products, Organogenesis’s PuraPly and PuraPly Antimicrobial products for wound management will be eligible for Medicare coverage and reimbursement in 10 states.

The states where Medicare will over coverages and reimbursements for these products are Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin. These states will add a total of 7.5 million consumers of PuraPly products.

Both PuraPly and PuraPly AM are categorized as FDA 510(k)-cleared Class II medical devices. These devices are used in the management of wounds including pressure ulcers, surgical wounds, trauma wounds, and venous and diabetic ulcers.

"We applaud the NGS for retiring its local coverage determination and making it easier for millions of Medicare patients to access clinically appropriate, advanced wound management products," said Gary S. Gillheeney Sr., President and CEO of Organogenesis. "We're excited that many more clinicians will now be able to use our versatile PuraPly product offerings to help Medicare patients more effectively manage a wide variety of acute and chronic wounds."